SEPN

Septerna, Inc. (SEPN) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Septerna, Inc. is a clinical-stage biotechnology company utilizing its proprietary Native Complex Platform to develop oral small molecule therapies targeting G protein-coupled receptors (GPCRs). The company is classified as an emerging growth company and a smaller reporting company. As of May 7, 2026, there were 45,075,533 shares of common stock outstanding.

Key Financial Metrics

Note: Revenue is derived primarily from the collaboration with Novo Nordisk. The company has no product sales revenue.

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased by approximately $26.3 million (12,011%) compared to Q1 2025. This is driven by the recognition of revenue from the Novo Collaboration Agreement, including $15.7 million from the upfront payment, $10.3 million in variable consideration for research services, and $0.5 million in milestone revenue.
• Reduced Net Loss: Net loss improved significantly from $21.5 million in Q1 2025 to $8.6 million in Q1 2026, primarily due to the substantial increase in revenue.
• Increased Operating Expenses: Total operating expenses rose by $13.7 million to $39.8 million. Research and Development (R&D) expenses increased by $10.3 million to $29.5 million, and General and Administrative (G&A) expenses increased by $3.4 million to $10.3 million. These increases are attributed to higher headcount, increased stock-based compensation, and expanded clinical and preclinical activities.
• Cash Position: Cash, cash equivalents, and marketable securities decreased by approximately $22 million to $522.1 million, reflecting net cash used in operating activities of $25.6 million and investing activities of $23.8 million.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities of $522.1 million are sufficient to fund operations and capital expenditure requirements at least into 2029.
• ATM Program: In March 2026, the company entered into an At-The-Market (ATM) Equity Offering Sales Agreement allowing for the sale of up to $150.0 million of common stock. No shares have been sold under this program as of March 31, 2026.
• Clinical Progress:
  • SEP-479: First participant dosed in Phase 1 clinical trial for hypoparathyroidism in April 2026. Data expected late 2026 or early 2027.
  • SEP-631: Phase 1 data presented at the AAAAI annual meeting in March 2026.
• Key Risks:
  • Development Uncertainty: The company has a limited operating history and has not successfully completed advanced clinical trials. Product candidates may fail to demonstrate safety or efficacy.
  • Regulatory & Geopolitical: Risks include potential FDA delays, government shutdowns, and the impact of the "BIOSECURE Act" on relationships with Chinese biotechnology providers (e.g., WuXi AppTec).
  • Collaboration Dependence: Revenue is heavily dependent on the Novo Nordisk collaboration. Failure of Novo to meet obligations or terminate the agreement would materially harm the business.
  • Capital Requirements: The company expects to continue incurring significant losses and will require substantial additional funding in the future.

Investor Verification Checklist

• Verify the specific terms and performance obligations of the Novo Nordisk Collaboration Agreement to understand the sustainability of the revenue stream.
• Monitor the progress and data readouts of the SEP-479 Phase 1 trial and SEP-631 program, as these are the most advanced assets.
• Assess the potential impact of the BIOSECURE Act on the company's supply chain, particularly regarding reliance on Chinese CDMOs.
• Review the company's burn rate and cash runway projections to confirm the ability to fund operations through 2029 without immediate dilution.
• Check for any updates on the ATM Program utilization and potential dilution from future equity issuances.